Core Viewpoint - Curanex Pharmaceuticals Inc. has successfully completed its initial public offering (IPO), raising a total of $17.25 million through the sale of 4,312,500 shares, with an additional 562,500 shares sold under the over-allotment option at $4.00 per share [1][2]. Group 1: IPO Details - Dominari Securities LLC acted as the lead underwriter for the IPO, with Pacific Century Securities LLC and Revere Securities LLC serving as co-underwriters [3]. - The IPO was registered with the SEC under Form S-1 and was declared effective on August 12, 2025 [4]. Group 2: Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focusing on botanical drugs for inflammatory diseases [6]. - The company's lead candidate, Phyto-N, is a botanical extract with anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [7].

Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focused on discovering and developing botanical drugs for inflammatory diseases [5] - The company's lead candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [5][6] Initial Public Offering (IPO) Details - Curanex announced the closing of its IPO, offering 3,750,000 shares of common stock at a price of $4.00 per share, resulting in gross proceeds of $15 million [1] - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025 [1] - Underwriters were granted an option to purchase up to 562,500 additional shares within 45 days from the closing of the Offering [1] Underwriters and Legal Counsel - Dominari Securities LLC served as the lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [2] - The Crone Law Group, P.C. acted as counsel to the company, while Sichenzia Ross Ference Carmel LLP served as lead counsel to the underwriters [2] Regulatory Filings - A registration statement on Form S-1 was filed with the SEC and declared effective on August 12, 2025, with the Offering made only by means of a prospectus [3]

Group 1 - Curanex Pharmaceuticals Inc. has priced its initial public offering (IPO) of 3,750,000 shares at $4.00 per share, aiming for gross proceeds of $15 million [1] - The IPO is expected to close on August 27, 2025, and shares will begin trading on the Nasdaq Capital Market under the ticker symbol "CURX" [1] - Underwriters have an option to purchase an additional 562,500 shares within 45 days of the offering's close [1] Group 2 - Proceeds from the offering will be used for the development of the lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required studies and IND application preparation [2] - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with Phyto-N being a botanical extract with proven anti-inflammatory properties [7][8] - Phyto-N has been validated in animal models for six inflammatory diseases, with the primary indication being moderate to severe ulcerative colitis [8] Group 3 - Dominari Securities LLC is the lead underwriter for the offering, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [3] - A registration statement for the offering was filed with the SEC and declared effective on August 12, 2025 [4] - The final prospectus related to the offering will be available on the SEC's website [4][5]